Amneal Pharmaceuticals, Inc. (AMRX)

6.50 -0.05 (-0.76%) 收市：04:00PM EDT

Amneal Pharmaceuticals, Inc.

400 Crossing Boulevard
3rd Floor
Bridgewater, NJ 08807
United States
908 947 3120
https://amneal.com

版塊: Healthcare
行業: Drug Manufacturers - Specialty & Generic
全職員工: 7,850

高階主管

名稱	頭銜	支付	行使價	出生年份
Mr. Chirag K. Patel	Co-Founder, Co-CEO, President & Director	1.71M	無	1967
Mr. Chintu Patel R.Ph.	Co-Founder, Co-CEO & Director	1.7M	無	1972
Mr. Anastasios G. Konidaris	Executive VP & CFO	1.04M	無	1967
Mr. Jason B. Daly Esq.	Senior VP, Chief Legal Officer & Corporate Secretary	779.06k	無	1974
Ms. Nikita Shah	Executive VP & Chief Human Resources Officer	848.83k	無	1979
Mr. Andrew S. Boyer	Executive VP & Chief Commercial Officer of Generics	1.2M	無	1966
Mr. Anthony DiMeo	Head of Investor Relations	無	無	無
Mr. Gregory Sgammato	Senior Vice President of Corporate Development	無	無	無
Mr. Pranav Mehta	Senior VP of Strategic Sourcing & Supply Management	無	無	無
Dr. Sanjay Kumar Jain Ph.D.	Chief Quality Officer	無	無	無

截止 2023年12月31日為止計算的金額，現金賠償則計算至上一個財政年度末止。薪資是指薪俸、獎金等。已行使價是指財政年度期間已行使的期權價值。貨幣為 USD。

描述

Amneal Pharmaceuticals, Inc., together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products. The Specialty segment develops, promotes, sells, and distributes pharmaceutical products with focus on central nervous system disorders, including Parkinson's disease, and endocrine disorders. This segment also provides Rytary, an oral capsule formulation of carbidopa-levodopa to treat Parkinson's disease, post-encephalitic parkinsonism, and parkinsonism; Unithroid for the treatment of hypothyroidism; and IPX203, a pipeline product for Parkinson's disease. The AvKARE segment offers pharmaceuticals, medical and surgical products, and services primarily to governmental agencies, the Department of Defense, and the Department of Veterans Affairs. This segment also distributes bottle and unit dose pharmaceuticals under the AvKARE and AvPAK names; and packages and distributes pharmaceuticals and vitamins to its retail and institutional customers. It sells its products through wholesalers, distributors, hospitals, chain pharmacies, and individual pharmacies. The company was formerly known as Atlas Holdings, Inc. and changed its name to Amneal Pharmaceuticals, Inc. in 2018. Amneal Pharmaceuticals, Inc. was founded in 2002 and is headquartered in Bridgewater, New Jersey.

公司管治

截至 2024年6月1日 止，Amneal Pharmaceuticals, Inc. 的 ISS 管治質素評分為 4。 Pillar 分數正在審核中：3；董事會：7；股東權利：4；現金賠償：3。

企業管治評分的資料提供： Institutional Shareholder Services (ISS). 評分將以 1 至 10 分顯示 (與指數或地區相關)。1 分表示較低的管治風險，而 10 分表示較高的管治風險。